Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus

Hypertension

Volumn 64, Issue 4, 2014, Pages 731-737

  Ferdinand, Keith C ^a   White, William B ^b   Calhoun, David A ^c   Lonn, Eva M ^d   Sager, Philip T ^e   Brunelle, Rocco ^f   Jiang, Honghua H ^g   Threlkeld, Rebecca J ^g   Robertson, Kenneth E ^g   Geiger, Mary Jane ^g,h  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e Sager Consulting Partners   (United States)

^f B2S Consulting   (United States)

^g ELI LILLY AND COMPANY   (United States)

^h REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

Ambulatory; Blood pressure; Blood pressure monitoring; Dulaglutide; Glucagon like peptide 1; Heart rate; Hypertension; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; DULAGLUTIDE; GLUCAGON LIKE PEPTIDE; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLYCOSYLATED HEMOGLOBIN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT;

AGED; AGONISTS; ANALOGS AND DERIVATIVES; BLOOD; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CHEMICALLY INDUCED; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; HEART RATE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VOMITING;

AGED; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DIABETES MELLITUS, TYPE 2; DIARRHEA; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCAGON-LIKE PEPTIDES; HEART RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NAUSEA; RECEPTORS, GLUCAGON; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; VOMITING;

EID: 84914666192     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.03062     Document Type: Article

References (27)

1. Meier JJ, Nauck MA. Glucagon-like peptide 1(GLP-1) in biology and pathology. Diabetes Metab Res Rev. 2005;21: 91-117.
2. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: Systematic review and meta-analysis. BMJ Open. 2013;24: 3.
3. Meigs JB. Epidemiology of cardiovascular complications in type 2 diabetes mellitus. Acta Diabetol. 2003;40(suppl 2): S358-S361.
4. Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens. 2010;23: 334-339.
5. Barrington P, Chien JY, Tibaldi F, Showalter HD, Schneck K, Ellis B. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab. 2011;13: 434-438.
6. Barrington P, Chien JY, Showalter HD, Schneck K, Cui S, Tibaldi F, Ellis B, Hardy TA. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide- 1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13: 426-433.
7. American Diabetes Association. Standards of medical care in diabetes- 2009. Diabetes Care. 2009;32(suppl 1): S13-61.
8. Dmitrienko A, Tamhane AC, Wiens BL. General multistage gatekeeping procedures. Biom J. 2008;50: 667-677.
9. Knudsen ST, Andersen NH, Poulsen SH, Eiskjaer H, Hansen KW, Helleberg K, Poulsen PL, Mogensen CE. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: A CALM II study post-hoc analysis. Am J Hypertens. 2008;21: 172-176.
10. Thase ME, Haight BR, Johnson MC, Hunt T, Krishen A, Fleck RJ, Modell JG. A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension. J Clin Psychopharmacol. 2008;28: 302-307.
11. Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ, 3rd. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: The EGO study. Diabetes Obes Metab. 2011;13: 418-425.
12. Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: Dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med. 2012;29: 1260-1267.
13. Barragan JM, Rodriguez RE, Blazquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol. 1994;266: E459-466.
14. Barragán JM, Rodríguez RE, Eng J, Blázquez E. Interactions of exendin-( 9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats. Regul Pept. 1996;67: 63-68.
15. Isbil-Buyukcoskun N, Gulec G. Effects of intracerebroventricularly injected glucagon-like peptide-1 on cardiovascular parameters; role of central cholinergic system and vasopressin. Regul Pept. 2004; 118: 33-38.
16. Nyström T, Gonon AT, Sjöholm A, Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept. 2005;125: 173-177.
17. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008; 117: 2340-2350.
18. Yu M, Moreno C, Hoagland KM, Dahly A, Ditter K, Mistry M, Roman RJ. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens. 2003;21: 1125-1135.
19. Halbirk M, Nørrelund H, Møller N, Holst JJ, Schmitz O, Nielsen R, Nielsen-Kudsk JE, Nielsen SS, Nielsen TT, Eiskjaer H, Bøtker HE, Wiggers H. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol. 2010;298: H1096-H1102.
20. Crajoinas RO, Oricchio FT, Pessoa TD, Pacheco BP, Lessa LM, Malnic G, Girardi AC. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol. 2011;301: F355-F363.
21. Hirata K, Kume S, Araki S, Sakaguchi M, Chin-Kanasaki M, Isshiki K, Sugimoto T, Nishiyama A, Koya D, Haneda M, Kashiwagi A, Uzu T. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun. 2009;380: 44-49.
22. Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, Gutmann H, Drewe J, Henzen C, Goeke B, Beglinger C. Glucagonlike peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab. 2004;89: 3055-3061.
23. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simpson JA, Drucker DJ. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med. 2013;19: 567-575.
24. Harsha DW, Bray GA. Weight loss and blood pressure control (Pro). Hypertension. 2008;51: 1420-5; discussion 1425.
25. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: A meta-analysis of randomized controlled trials. Hypertension. 2003;42: 878-884.
26. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33: 187-215.
27. Eli Lilly and Company. Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND). clinicaltrials.gov. Bethesda, MD: National Library of Medicine; 2011-2013. NLM Identifier NCT01394952.